Clinical trial NCT06854016: Performance and Safety of LightForce® Therapy Lasers on Lateral Ankle Sprain
Official title: Randomized, Sham Controlled, Single Blind Study on the Performance and Safety of Photo Biomodulation Therapy (PBMT) With LightForce® Therapy Lasers on Lateral Ankle Sprain Pain Reduction
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Ankle Sprain 1St Degree
Ankle Sprain 2Nd Degree
Acute Pain
Keywords: lateral acute grade I and II ankle sprain, pain, laser
Lead sponsor: DJO UK Ltd
Sponsor class: INDUSTRY
First posted: 2025-03-03
Enrollment: 108
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: DJO UK Ltd (ENOVIS) is conducting this study to assess the effectiveness of LightForce® Therapy Lasers on pain reduction in subjects with ankle soft tissue trauma and/or sport injury. In detail this study will assess superiority of LightForce® Therapy Lasers combined with standard of care, represented by RICE and physiotherapy/exercise program, compared to sham laser combined with standard of care (RICE and physiotherapy/exercise program) on pain reduction in subjects with acute grade I - II lateral ankle sprain. In addition, this study allows to collect post market clinical data on the safety and performance of LightForce® Therapy Lasers, when used, following the normal clinical practice, in accordance with its approved and CE marked intended use.

Detailed description: This clinical investigation is a post-market, International, multi center, prospective, randomized, sham controlled, single blind study to assess the effectiveness of LightForce® Therapy Lasers and to collect PMCF data on the safety and performance of LightForce® Therapy Lasers when used in accordance with its approved labeling, to comply with Medical Device Regulation (EU) 2017/745 (MDR) Article 61 and Part B of Annex XI.

Eligibility criteria: Inclusion Criteria:

1. Patient male or female with age ≥18 years old
2. Patient with diagnosis of LAS (as confirmed by physical examination) to be treated by LightForce® Therapy Lasers according to its indications.
3. Patient suffering from LAS pain for no more than 72 hours prior to enrollment
4. Pain (either persistent or during activities) score reported by the subject at baseline ≥ 40 mm measured on VAS
5. Patient able to provide written informed consent

Exclusion Criteria:

1. Patient with musculoskeletal pathological conditions not to be treated with/contraindication to the use of LightForce® Therapy Lasers according to its intended use and indications
2. Patients who are taking drugs that have heat or light sensitive contraindications, such as but not limited to certain types of steroids
3. Patients who have been administered with corticosteroids after injury
4. Pregnant females or females of childbearing potentially planning to become pregnant during the study participation
5. Patients who had systemic inflammatory conditions (i.e. rheumatoid arthritis, polymyalgia rheumatica)
6. Patients affected by chronic ankle instability (recurrent sprains, ankle instability, functional ankle instability, mechanical ankle instability fol¬lowing the first-time injury)
7. Patients with bilateral ankle sprain
8. Patients who have a disease that would limit their participation in exercises (i.e. severe chronic obstructive pulmonary disease, severe heart failure, cerebrovascular event history)
9. Patients with fractures (as confirmed by radiological examination)
10. Patients with a diagnosis of active cancer
11. Patients with tattoos covering more than 30% of the area to be treated with LightForce® Therapy Lasers
12. Patients who are mentally or physically incapacitated
13. Patient participating in other clinical study or has completed a clinical study less than 30 days prior to enrollment
14. Patients with other clinically significant co-morbidities that make the patient unsuitable for study participation, at the discretion of the investigator

Primary outcomes:
measure: Pain change
timeFrame: 2 weeks after treatment start
Secondary outcomes:
measure: Safety - adverse event rate
timeFrame: through study completion, an average of 12 weeks
Other outcomes:
measure: Pain change
timeFrame: 1,3,4, 6 and 12 weeks after treatment start
measure: Ankle pain and Disability
timeFrame: 1, 2, 3, 4, 6 and at 12 weeks after treatment start
measure: Patient overall status change
timeFrame: 2, 4, 6 ans 12 weeks after treatment start
measure: Range of motion (ROM) of the ankle
timeFrame: 1, 2, 3, 4, 6 and 12 weeks after treatment start
measure: Return to pre-injury activity/sport level
timeFrame: 2, 3, 4, 6 and 12 weeks after treatment start
Locations:
city: Cassano D'adda
country: Italy
facility: Carioni Fisioterapia
state: Milano
city: Caserta
country: Italy
facility: Casertafisio
city: Roma
country: Italy
facility: Fisioterapia Eur
city: Roma
country: Italy
facility: Fisioterapia Gardenie
city: Leeds
country: United Kingdom
facility: INDERGAARD PHYSIOTERAPY Ltd
Study officials:
affiliation: ove@indergaardphysio.com
name: Ove Indergaard, Physiotherap
role: PRINCIPAL_INVESTIGATOR
References: